生物制药公司PMV Pharmaceuticals宣布,其针对TP53 Y220C突变卵巢癌的候选药物Rezatapopt,预计将于2027年第一季度向监管机构提交新药申请。该时间表标志着公司在该精准疗法开发道路上的一个重要里程碑。
生物制药公司PMV Pharmaceuticals宣布,其针对TP53 Y220C突变卵巢癌的候选药物Rezatapopt,预计将于2027年第一季度向监管机构提交新药申请。该时间表标志着公司在该精准疗法开发道路上的一个重要里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.